| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
Ethopropazine Hydrochloride targets butyrylcholinesterase (BChE), an enzyme that hydrolyzes choline esters. It is a potent and specific inhibitor of BChE, with an IC50 of 15.14 µM in human erythrocyte lysates. It is selective for BChE over acetylcholinesterase (AChE) at 500 µM. By inhibiting BChE, Ethopropazine Hydrochloride modulates cholinergic signaling. It also has anticholinergic properties.
|
|---|---|
| ln Vitro |
In vitro, Ethopropazine Hydrochloride is a potent inhibitor of BChE with an IC50 of 15.14 µM in human erythrocyte lysates. It is selective for BChE over AChE. Its activity is typically measured using enzyme assays with BChE and a chromogenic substrate. These in vitro studies confirm the compound's activity as a BChE inhibitor.
|
| ln Vivo |
In vivo, Ethopropazine Hydrochloride is used in research for Parkinson's disease. Its anticholinergic properties may help to reduce tremors and other symptoms associated with Parkinson's disease. However, specific in vivo protocols and results are not detailed in standard product descriptions.
|
| Enzyme Assay |
In vitro enzyme assays for Ethopropazine Hydrochloride measure its inhibition of butyrylcholinesterase (BChE) activity. BChE is incubated with a chromogenic substrate (e.g., butyrylthiocholine) in the presence of varying concentrations of Ethopropazine Hydrochloride. The hydrolysis of the substrate produces a colored product that is measured spectrophotometrically. The IC50 is determined from dose-response curves.
|
| Cell Assay |
In vitro cell-based assays for Ethopropazine Hydrochloride are used to study its effects on cholinergic signaling. Cells expressing BChE are treated with Ethopropazine Hydrochloride, and the hydrolysis of choline esters is measured. The compound's ability to inhibit BChE activity is assessed.
|
| Animal Protocol |
In vivo animal experiments for Ethopropazine Hydrochloride are not extensively described in the available literature. As a research compound, its use in vivo would be determined by the specific research question being addressed. A typical protocol for studying a BChE inhibitor would involve its administration to animal models of neurological disorders. However, specific protocols for Ethopropazine Hydrochloride are not detailed.
|
| ADME/Pharmacokinetics |
Ethopropazine Hydrochloride has a molecular weight of 348.9 g/mol and a molecular formula of C19H25ClN2S. It has a CAS number of 1094-08-2. It is a solid compound. For storage, it is recommended to keep the powder at -20°C. Detailed pharmacokinetic properties such as absorption, distribution, metabolism, and excretion (ADME) have not been extensively characterized.
|
| Toxicity/Toxicokinetics |
Detailed toxicity data for Ethopropazine Hydrochloride is not provided in standard product descriptions. As a phenothiazine compound, it may have side effects similar to other drugs in this class, including anticholinergic effects. As with all research chemicals, standard laboratory safety precautions should be followed when handling Ethopropazine Hydrochloride.
|
| References |
|
| Additional Infomation |
Profenamide hydrochloride is the monohydrochloride salt of propfenamide. It is an antimuscarinic drug used for the symptomatic treatment of Parkinson's disease. It has the effects of an adrenergic antagonist, histamine antagonist, anti-Parkinson's disease drug, and muscarinic antagonist. It contains propfenamide.
Ethopropazine Hydrochloride is a research compound and a pharmaceutical agent. It is a phenothiazine compound with anticholinergic properties. It is a potent and specific inhibitor of butyrylcholinesterase (BChE) and a poor inhibitor of acetylcholinesterase (AChE). It is used in research for Parkinson's disease. Ethopropazine Hydrochloride is a valuable research tool for studying BChE and cholinergic signaling. |
| Molecular Formula |
C19H25CLN2S
|
|---|---|
| Molecular Weight |
348.93
|
| Exact Mass |
348.143
|
| CAS # |
1094-08-2
|
| Related CAS # |
1094-08-2 (HCl);522-00-9;
|
| PubChem CID |
122824
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
430.1ºC at 760 mmHg
|
| Melting Point |
225 - 228 °C
|
| Flash Point |
213.9ºC
|
| Vapour Pressure |
1.34E-07mmHg at 25°C
|
| LogP |
5.886
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
23
|
| Complexity |
322
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCN(CC)C(C)CN1C2=CC=CC=C2SC3=CC=CC=C31.Cl
|
| InChi Key |
VXPCQISYVPFYRK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H24N2S.ClH/c1-4-20(5-2)15(3)14-21-16-10-6-8-12-18(16)22-19-13-9-7-11-17(19)21;/h6-13,15H,4-5,14H2,1-3H3;1H
|
| Chemical Name |
N,N-diethyl-1-phenothiazin-10-ylpropan-2-amine;hydrochloride
|
| Synonyms |
Ethopropazine Hydrochloride; Pardisol; Dibutil; Parphezein; Profenamine HCl Parfezin;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~71.65 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.16 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.16 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.16 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8659 mL | 14.3295 mL | 28.6590 mL | |
| 5 mM | 0.5732 mL | 2.8659 mL | 5.7318 mL | |
| 10 mM | 0.2866 mL | 1.4330 mL | 2.8659 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
